Clinical Trail
VASO - NOX - OL ( formerly Panoxol)
The following contents include genuine research on Panoxol, now Vasonoxol. This clinical experience research on Vasonoxol as an adjunct for hypertension is derived from a compensated clinical study. Best practices were implemented to intentionally obscure all confidential and identifiable information, thereby presenting the authentic results of the investigation on the United States patented Panoxol, now marked as Vasonoxol®.
In summary, all participants began the study in a Stage 2 hypertensive, Stage 1 hypertensive, or pre-hypertensive state. At the conclusion of the study, a large segment of the participants were no longer hypertensive.
Please feel free to share this information with your doctor or healthcare professional.
Cordially,
Clinical and Herbal Innovations Inc
🕒 Estimated reading time: 4 minutes, 20 seconds.
Overall Clinical Experience Design
Clinical Experience Study: A multicenter study of the safety and effectiveness of Panoxol for health of patients with Hypertensive Conditions
Clinical Objective: To demonstrate the safety and effectiveness Panoxol for health of patients with Hypertensive Condition.
Structure: Multicenter, randomized, no control group
Duration: 8-week enrollment and a 16-week usage plan with Panoxol Formula, now US Trademarked by Clinical and Herbal Innovations Inc. as Vasonoxol.
Controls: A fifty (50) “No Initial Treatment Group” is utilized vs. standard therapy.
Clinical Hypotheses: At least sixty percent (60%) of Subjects utilizing Panoxol will be responders within sixteen (16) weeks and show an improvement of twenty percent (20%) in the JACKSON HYPERTENSION STUDY questionnaire measurement technique by Subject Self-Assessment.
Product: Vasonoxol® is the name given by Clinical and Herbal Innovations Inc. to its doctor-formulated, US patented formula used in the Villages study. Panoxol™ is one of the brand names under which Vasonoxol is currently marketed.
Dose Regimen: Vasonoxol is used daily. The Treating Investigator instructs the Subjects to swallow two tablets of Panoxol with at least eight ounces (8 oz.) of water twice daily. The Treating Investigator can increase the maximum usage for Subjects with larger frames (over BMI 32).
Highlight of Subject Reports:
Question # 1 “Over the past 6 months: How do you rate your confidence that you blood pressure is under control?”
Observed Summary: Thirty-five participants reported improved confidence in their ability to control their blood pressure. More detailed analysis demonstrates that those who initially responded, “very poorly” (meaning they were not confident their blood pressure was under control), 100% (4) of them reported improvement by the end of the study (average score 4). For those who responded poorly (2 out of 5), 100% of them (9) reported improvement by the end of the study (average score 4.1). This means that those who were most concerned about controlling their blood pressure found confidence through Vasonoxol.
Question # 2: “When you awake in the morning, how often were you dizzy when you woke up?”
Observed Summary: Twenty-seven participants reported improvement on question # 2.
Question # 3 “During your normal day, how often were you dizzy or have problems maintaining your balance?”
Observed Summary: Thirty-six participants reported improvement on question # 3.
Question # 4 “During your normal day, how often did you feel 'light-headed' or dizzy?”
Observed Summary: ”Thirty-nine participants reported improvement on question # 4.
Question # 5 “When you attempted a sexual interlude, how often was it satisfactory for you?”
Observed Summary: No significant change was observed during the study.
Overall, 92 participants would recommend Panoxol to family and friends
Participant Feedback
|
Henry |
“Panoxol taken with my blood pressure medicine has made a huge difference. I feel so much better now that my blood pressure has been under control for 3 months.” |
|
Jacob |
“This has made me feel 100% better.” |
|
Lori |
“I have had a lot of improvement with taking Panoxol” |
|
Maryann |
“Panoxol has helped me so much” |
|
Shawn |
“Seems to help a lot.” |
|
Stacy |
“I plan on taking this medication from now on.” |
|
Caleen |
“This product is amazing!” |
|
Ammon |
“I haven't seen a big change, but I don't normally have high blood pressure. I do, however, think it will help people that do. I do feel more energetic.” |
Special Report on Vasonoxol®
and Blood Pressure Study Findings
Overview:
Out of ninety-seven participants, seventy-eight completed records showed a reduction in blood pressure by the study's conclusion. Participants, on average, experienced a decrease of 7 points (5%) in systolic pressure and an 11-point (20%) reduction in diastolic pressure. Detailed analysis indicates that Vasonoxol ( formerly called Panoxol ) is particularly effective in lowering blood pressure in individuals with stage 1 or stage 2 hypertension.
AVERAGE SCORES BY HYPERTENSION STAGES
Sorted Systolic
|
Category |
# Participants |
Systolic/Diastolic |
|
|
Normal Blood Pressure |
(90-119) |
[four] |
-7 / -11.2 |
|
Pre-Hypertension |
(120-139) |
[sixty-five] |
-3.5 / -8.8 |
|
Hypertension Stage 1 |
(140 -159) |
[twenty-three] |
-15.1 / 16.7 |
|
Hypertension Stage 2 |
(160—179) |
[four] |
-24.5 / -25 |
Sorted by Diastolic
|
Category |
# Participants |
Systolic/Diastolic |
|
|
Normal Blood Pressure |
(less than 80) |
[eighty one] |
-5/-9 |
|
Pre-Hypertension |
(80-89) |
[fourteen] |
--15/-24 |
|
Hypertension Stage 1 |
(90-99) |
[one] |
--30/-47 |
|
Hypertension Stage 2 |
(99+) |
[none] |
|
REDUCTION OF SYSTOLIC SCORES BASED ON HYPERTENSION STAGE
SUMMARY OF RESULTS BY CATEGORY
|
|
Day 1 |
Day 90 |
|
Normal |
4 |
20 |
|
Prehypertension |
65 |
69 |
|
Hypertension Stage 1 |
23 |
3 |
|
Hypertension Stage 2 |
4 |
1 |
BLOOD PRESSURE SUMMARY
Those who began the study with Normal Systolic Blood Pressure (90-119), experienced an average of 7 mm drop in their systolic pressure. At the end of the study, all four remained in the “Normal” range.
Participants who started with Prehypertension readings (120-139) [sixty-five] exhibited an average systolic pressure drop of 3.5 mm. By the study's end, 16 individuals had lowered their blood pressure sufficiently to enter the Normal range, while 49 remained in Prehypertension. Among these, 28 reported improved scores but stayed in the Prehypertension category. A significant finding emerged from those beginning in Hypertension Stage 1 (140-159) [twenty-three], who had an average reduction of 15.1 mm, with eighty-seven percent [20 participants] showing a decrease substantial enough to shift to the Prehypertension category. Only three who began in Stage 1 remained at the study's conclusion. The most remarkable outcomes were seen in participants who started in Hypertension Stage 2 (160—179); every single participant (4) successfully reduced their blood pressure by at least one category, and three out of four achieved enough reduction to qualify for the Prehypertension category (two stages lower).
Summary of the Vasonoxol® Study as a Hypertension Adjunct
Every participant successfully reduced their blood pressure by at least one category, and three out of four achieved enough reduction to qualify for the Prehypertension category (two stages lower).Our participants’ responses aligned with the aim of this study. They did not report any hypotensive results (patients’ blood pressure dropping below the normal range). Additionally, they reported experiencing some reduction in side effects commonly associated with high blood pressure medications.